GRTX galeratx.com: Enterprise Value to EBITDA Ratio

Brandmark of Galera Therapeutics (GRTX)

The quote characteristics for Galera Therapeutics (GRTX) on GURU.Markets based on the separate_ev_ebitda metric are . Galera Therapeutics (GRTX) is implementing digital systems for remote monitoring of trial participants to eliminate manual data entry. The firm previously developed radiation protection agents based on mimetics. Currently, due to FDA prohibitions, the company is shutting down development and distributing remaining cash funds to shareholders.

GRTX Galera Therapeutics Inc.: Company Value to Operating Income Before Depreciation Ratio in the range 07/04/2022 - 11/15/2026

Metric breakdowns and analytics for Galera (GRTX)

General company analysis:Galera Therapeutics GRTX
Product sample of Galera Therapeutics Inc.

Galera Therapeutics (GRTX) is in a critical state due to failed clinical trials and a loss of confidence in management. This indicator compares the total enterprise value, including debt, with its operating profit, revealing the asset's real value regardless of financial manipulations. By analyzing the Galera Therapeutics (GRTX) EV/EBITDA multiple chart, investors determine whether the current low valuation is a sign of undervaluation or a precursor to the biotech's imminent bankruptcy.